Price
$14.97+34.74%Social Signal Score
Analyst Ratings
15 analysts52-week range
- Last close
- $14.97
- Off 52w high
- -1.8%
- 200-day average
- $8.14
- vs 200-day
- +83.9%
Revenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Sushil Patel
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 465
- Beta
- 0.94
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -5.94
Financials
Net Income
$-69.77MEBITDA
$-66.02MFree Cash Flow
$-75.73MEPS (diluted)
$-0.72Shares Outstanding (diluted)
96.86M+214.1%Operating Expenses
$68.25MCash & Debt
$195.33MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $0.00 | $-313.94M | $-3.38 |
| 2025 | $0.00 | $-247.30M | $-3.07 |
| 2024 | $0.00 | $-215.79M | $-3.24 |
| 2023 | $0.00 | $-174.28M | $-2.99 |
| 2022 | $0.00 | $-118.04M | $-2.26 |
| 2021 | $0.00 | $-80.87M | $-1.75 |
| 2020 | $0.00 | $-52.63M | $-1.54 |
| 2019 | $0.00 | $-30.83M | $-1.33 |
| 2018 | $0.00 | $-19.70M | $-0.64 |
| 2017 | $0.00 | $-7.70M | $-0.36 |
Valuation
REPLhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50Social Signal Score
Mentions (8)
- Newsglobenewswire.com·4d ago·Neutral
Replimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma ReplimuneConnect Plus a comprehensive program that provides dedicated support and resources to help eligible patients access TUDRIQEV in the U.S. now live ReplimuneConnect Plus a comprehensive program that provides dedicated support and resources to help eligible patients access TUDRIQEV in the U.S. now live
View source ↗ - Newsseekingalpha.com·20d ago·Neutral
Replimune Group, Inc. (REPL) Shareholder/Analyst Call Prepared Remarks Transcript Replimune Group, Inc. (REPL) Shareholder/Analyst Call Prepared Remarks Transcript
View source ↗ - Newsglobenewswire.com·41d ago·Negative
REPL Stockholders Have Rights – If You Lost Money Investing in Replimune Group, Inc. Contact Robbins LLP for Information About Recovering Your Losses Robbins LLP is Investigating Allegations that Replimune Group, Inc. Misled Investors Regarding the Efficacy and Viability of its Lead Product Candidate RP1
View source ↗ - Newsglobenewswire.com·47d ago·Neutral
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) WOBURN, Mass., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to Michelle DiNapoli, the Company's Chief Commercial Officer.
View source ↗ - Newsglobenewswire.com·53d ago·Neutral
…ted financing extends cash runway to support commercial launch and confirmatory trial WOBURN, Mass., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal first quarter ended June 30, 2026 and provided a business update.
View source ↗ - Newszacks.com·56d ago·Positive
Here's Why Replimune Stock Skyrockets Nearly 223% in 3 Months REPL's RP1 secures FDA approval for advanced melanoma, easing regulatory uncertainty. The company expands its oncolytic immunotherapy pipeline.
View source ↗ - Newsbusinesswire.com·57d ago·Neutral
Replimune Group, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – REPL LOS ANGELES--(BUSINESS WIRE)---- $REPL--Replimune Group, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – REPL.
View source ↗ - Newsbusinesswire.com·59d ago·Negative
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with SBS Law LOS ANGELES--(BUSINESS WIRE)---- $REPL--REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with SBS Law.
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $-0.78 per share
Typical surprise -4.1% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Aug 14$-0.72 vs $-0.69miss
- Mon, Jun 29$-0.76 vs $-0.73miss
- Tue, Feb 3$-0.77 vs $-0.77miss
- Thu, Nov 6$-0.90 vs $-0.87miss
- Thu, Aug 7$-0.95 vs $-0.83miss
- Thu, May 22$-0.82 vs $-0.75miss
Estimates and results for REPL via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by REPL officers and directors.
- Bought
- $274
- Sold
- $3.7m
2 trades
36 trades
- Hill Emily Luisasold
- Baker Bros. Advisors Lpbought
- Baker Bros. Advisors Lpbought
- Patel Sushilsold
- Hill Emily Luisasold
- Xynos Konstantinossold
- Schwendenman Andrewsold
- Sarchi Christophersold
62 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in REPL.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.